Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs
March 29, 2023 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the 12 months ended December 31, 2022, and provides updates on its antiviral...
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
February 15, 2023 08:00 ET
|
Assembly Biosciences, Inc.
−ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN...
Pardes Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 07, 2022 16:01 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug...
The antiviral drugs market is anticipated to grow at a CAGR of 6.3% during the period 2022-2035, claims Roots Analysis
November 01, 2022 15:00 ET
|
Roots Analysis
London, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Antiviral Drugs Market, 2022 – 2035” report to its list of offerings. The recent COVID-19 pandemic has...
Pardes Biosciences to Present at Jefferies London Healthcare Conference
November 01, 2022 08:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel...
Global Conjunctivitis Treatment Market Size to Reach USD 6.1 Billion by 2031: Allied Market Research
October 03, 2022 13:14 ET
|
Allied Market Research
Portland, OR, Oct. 03, 2022 (GLOBE NEWSWIRE) -- A new business intelligence report released by Allied Market Research, the global Conjunctivitis Treatment Market generated $4.2 billion in 2021, and...
Pneumonia Therapeutics Market Estimated to Generate $3,147.7 Million and Grow at 8.2% CAGR by 2027 Post Covid-19 Pandemic | Confirmed by Research Dive
September 27, 2022 09:01 ET
|
Research Dive
New York, USA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global pneumonia therapeutics market is estimated to generate a revenue of $3,147.7 million...
Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of Directors
September 14, 2022 08:00 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (Nasdaq: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel oral...
Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections
September 13, 2022 08:00 ET
|
Pardes Biosciences, Inc
Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo Interim data from Phase 2 anticipated in Q1...
Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 12, 2022 08:30 ET
|
Pardes Biosciences, Inc
CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel...